Pros and Cons of Genus plc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genus plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genus plc | -1.350% | -3.311% | 8.955% | 47.475% | 63.128% | -13.609% | -33.697% |
| Ironwood Pharmaceuticals | -2.550% | 4.795% | 19.531% | -8.383% | -27.143% | -73.167% | -68.934% |
| Novocure Ltd | -1.160% | 9.135% | 15.722% | -60.508% | -61.023% | -84.133% | -91.990% |
| Iovance Biotherapeutics Inc. | 0.650% | -0.393% | -14.490% | -75.357% | -72.809% | -71.362% | -95.447% |
Comments
Genus (OTCMKTS:GENSF) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for GENSF provided by MarketBeat